MIRA INFORM REPORT

 

 

Report Date :           

20.04.2012

 

IDENTIFICATION DETAILS

 

Name :

BIOTEQUE CORPORATION

 

 

Registered Office :

5FL.-6, No.23, Sec.1, Chang-An E. Rd., Taipei 104

 

 

Country :

Taiwan

 

 

Financials (as on) :

31.12.2011

 

 

Date of Incorporation :

13.11.1991

 

 

Com. Reg. No.:

86306206

 

 

Legal Form :

Joint Stock Company

 

 

Line of Business :

Manufacture and sales of medical supplies

 

 

No. of Employees :

About 350 employees

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Maximum Credit Limit :

USD 250,000

 

 

Status :

Satisfactory

 

 

Payment Behaviour :

No Complaints

 

 

Litigation :

Clear

 

 

NOTES:

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st, 2012

 

Country Name

Previous Rating

                   (31.12.2011)                  

Current Rating

(31.03.2012)

Taiwan

a2

a2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


Contact Points

 

Company Name:

Bioteque Corporation

Supplied Name:

Biioteque Corporation

Trading Address:

5FL.-6, No.23, Sec.1, Chang-An E. Rd., Taipei 104, Taiwan, R.O.C.

Supplied Address:

5F, 6No. 23 Sec 1 Chang An East Road Taipei 104

Telephone Number:

+886-2-2571-0269

Fax Number:

+886-2-2536-1967

E-mail:

sales@bioteq.com.tw

Notes: Subject’s exact name and address are as above.

 

 

Credit Summary

 

Credit Rating:

Maximum credit USD 250,000

Credit Opinion:

Business connections are permissible.

 

 

Company Identification Details

 

Registered Name:

Bioteque Corporation

Registered Address:

5FL.-6, No.23, Sec.1, Chang-An E. Rd., Taipei 104, Taiwan, R.O.C.

Date of Foundation:

1991-11-13

Registration Number:

86306206

Registry:

Department of Commerce, Ministry of Economic Affairs, R.O.C.

Registered Capital:

NTD 1,200,000,000 (USD 40,680,000)

(As of 2012.04, 1 NTD = 0.0339 USD)

Paid-up Capital:

NTD 782,769,360 (USD 26,535,881)

Legal Representatives:

Zongli Cai

Legal Form:

Joint Stock Company

Principal Activities:

Manufacture and sales of medical supplies

Staff:

About 350 employees

Listed at Stock Exchange:

Yes TPO:4107

Date of Last Annual Return:

2010-6-24

 

 

History

 

Subject was incorporated on 1991-11-13 with registered number 86306206 as Joint Stock Company in Taiwan.

 

Change of Name

Former Chinese Name

邦拓生物科技股份有限公司

Current Chinese Name

邦特生物科技股份有限公司

Awards

Year

Awards

2008

Blue chip importer and exporter

2009

Blue chip importer and exporter

2010

Blue chip importer and exporter

Standard of Blue chip importer and exporter

Unit: USD

Year

Amount

2008

19,000,000

2009

15,000,000

2010

20,000,000

 

 

Shareholders

 

Name

Subscription Shares

Zongli Cai

3,909,000         

 

Mingzhong Li

 

1,582,313

 

Bangyan Zhang

1,002,648

Excelsior Medical Co., Ltd.

1,545,000

Junyao Lin

2,600,000

Hailu Chen

828,835

Yixun Li

1,412,928

Shiguang Lv

2,428,984

King Polytechnic Engineering Co., Ltd.)

709,519

Qinyi Li

422,567

 

The information above is that of subject’s major shareholders.

 

 

Subsidiaries & Branches

 

Branch

Branch Registered Number

28971553  

Branch Name

Yilan Branch

Branch Manager

Yixun Li   

Branch Address

No. 5, Ziqiang Road, Longde Lane, Suao Town, Yilan County, Taiwan

Date of Incorporation

2008-11-14  

 

 

Personnel Information

 

Core Management

Directors

1

Name

Zongli Cai

Position

President

2

Name

Mingzhong Li

Position

Vice President

3

Name

Bangyan Zhang

Position

Director

4

Name

Mingting Wang

Position

Director

5

Name

Junyao Lin

Position

Director

6

Name

Hailu Chen

Position

Director

7

Name

Yixun Li

Position

Director

8

Name

Shiguang Lv

Position

Supervisor

9

Name

Zhenpan Hong

Position

Supervisor

10

Name

Qinyi Li

Position

Supervisor

 

Personnel Structure

Total Employees

About 350 employees

 

 

Operation Information

 

Offices & Factories

 

Headquarters

Add

5FL.-6, No.23, Sec.1, Chang-An E. Rd., Taipei 104, Taiwan, R.O.C.

Plant Area

About 20,000 square feet

 

Production Information

l         Subject is a manufacturer of medical supplies

l         It is introduced that subject has obtained the certification of GMP, ISO9001, ISO13485, CE0434 and FDA 510 (K), etc

 

Purchase Information

l         The registered activities of subject:

Business Code

Details

CF01011 

Manufacture of medical equipments

F108031 

Wholesales of medical equipments

F208031 

Retails of medical equipments

ZZ99999 

Besides licensed business, all other business items those are not banned or restricted.

 

l         Subject’s products are mainly made of TPU, Silicon, PTFE, PFA, Nylon, etc

l         Subject purchases both at home and abroad.

 

Sales Information

l         The subject is mainly engaged in sales of medical supplies including Kidney tube, puncture needle, Precision infusion set, Senior medical soft bag, urine bag, canal and other Medical personnel supplies, etc

l         Subject’s products are applied to nephrology, urology, radiology, Cardiology, Respiratory Therapy, Critical Care, iv administration therapy and molding parts, etc

l         Subject’s products are both sold in domestic and overseas market and it is introduced that subject exports to over 40 countries in America, Europe, Asia and Africa.

 

Import and export right:

Import right

Yes

Export right

Yes

Settlements

 

Purchase

Domestic Purchase

Product

Payment Terms

Proportion

Raw materials, etc

COD, Credit Sales, etc

100%

 

Foreign Purchase

Product

Payment Terms

Proportion

Raw materials, etc

CBD, etc

100%

 

Sales

Domestic Markets

Product

Sales Terms

Proportion

Medical supplies

CBD, etc

100%

Export

Product

Sales Terms

Proportion

Medical supplies

CBD, etc

100%

 

 

Balance Sheet

 

Unit: NTD/000

 

2011-12-31

2010-12-31

Cash And Cash Equivalents

78,472

88,758

Net Notes Receivable

31,018

27,238

Net Accounts Receivable

112,892

114,783

Other Financial Assets-Current

3

2

Current Assets

624,122

699,009

Inventories-selling industry

1,144

.

Inventories

105,221

106,806

Inventories-manufacturing

104,077

106,806

Finished Products

20,437

21,625

goods in progress

24,735

20,637

Raw materials

51,733

60,475

Materials and supplies intransit

7,172

4,069

The allowance for depreciation and sluggish stock losses

.

.

Other Current Assets

9,773

8,054

Restricted Current Assets

1,201

1,201

Other Current Assts-Others

8,572

6,853

Changes in the fair value of the financial assets on profit and loss-current

286,743

353,368

Investment

266,243

227,676

Long-Term Investments at equity

266,243

227,676

Other financial Assets-Non Current

674

701

Financial Assets for sales-Non current

1,127

2,255

Fund and Investment

268,044

230,632

Land

100,334

100,334

Building and structure

396,041

393,121

Machine Equipment

438,724

433,720

Transporting Equipment

4,237

3,722

Office Equipment

18,722

14,181

Total Fixed assets cost

1,015,767

1,002,995

Machinery Revaluation Increments

.

.

accumulated depreciation

-298,346

-262,353

Net Fixed Assets

733,239

753,901

Cost and value through revaluation totals

1,015,767

1,002,995

Unfinished project and equipment funds in advance

15,818

13,259

Unfinished project

.

156

Equipment Funds In Advance

15,818

13,103

Other devices

57,709

57,917

Deferred Pension Costs

.

374

Total Intangible Assets

.

374

Deferred charges

2,832

1,060

Total Other Assets

2,832

1,060

Total Assets

1,628,237

1,684,976

Shortterm Borrowing

.

.

Notes Payable

19,728

29,873

Account Payable

39,197

32,778

Income Tax Payable

1,535

18,857

Accrued Charge

48,384

47,443

Financial liabilities at fair value through profit or loss-current

.

509

Current Liabilities;

167,097

167,683

Other payables

3,912

4,319

Dividends Payable

.

.

Payables on equipment

3,912

4,319

Long-Term Liabilities -Current Portion

32,650

17,650

Long-Term loan-Current Portion

32,650

17,650

Other Current Liabilities

21,691

16,254

Long-Term Loan

172,475

205,125

LongTerm Bank Loans

172,475

205,125

Longterm Liabilities

172,475

205,125

Pension prepared/ accrued pension liabilities

2,462

4,785

Guarantee Deposit Received

10

.

Deferred Income Tax

36,289

41,329

Deferred Income Tax Liabilities-Non Current

36,289

41,329

Other Liabilities-Others

8,941

22,831

Other Liabilities-Others

8,941

22,831

Total Other Liabilities

47,702

68,945

Total Liabilities

387,274

441,753

Common Stock

782,769

782,769

Capital Stock

782,769

782,769

Capital Reserve- Share Premium Account

83,003

83,003

Capital Reserve-Common Stock Premium

76,104

76,104

Capital Reserve- Convertible debt conversion premium

6,899

6,899

Total capital reserve

83,003

83,003

Legal Surplus

105,507

88,248

Special Reserve

53,270

27,603

Unappropriated Retained Earnings

259,643

314,870

Accumulated Profit Or Loss

259,643

314,870

Total Retained Earnings

418,420

430,721

Cumulative Translation Adjustment

-31,816

-40,892

Share Capital- share premium

.

-2,093

Unrealized gain or loss on financial instrument

-11,413

-10,285

Total Shareholders' equity other adjustment

-43,229

-53,270

Equivalent Shares of Outstandings of Advance Receipts for Common Stock (Unit: Share)

.

.

Number of Treasury Stock Acquired by  Parent Company and Subsidiaries (unit: Share)

.

.

Total shareholders' equity

1,240,963

(USD 42,068,646)

1,243,223

(USD 42,145,260)

(As of 2012.04, 1 NTD = 0.0339 USD)

 

 

Profit and Loss Account

 

Unit: NTD/000

 

2011

2010

Total operation revenue

759,437

(USD 25,744,914)

821,623

(USD 27,853,020)

Net sales revenue

759,437

821,623

Total sales revenue

759,956

826,161

sales returns

519

4,538

sales discounts and allowances

.

.

Total Cost Of Sales

519,937

512,613

cost of goods sold;

519,937

512,613

Operating margin (Loss)

239,500

309,010

Total operating expenses

133,414

133,388

Distribution Cost

49,250

55,674

General Andadministrative Expenses

36,876

36,183

Research And Development Expenses

47,288

41,531

Net Operating Profit (loss)

106,086

175,622

Non-operating revenue and profit

36,805

36,155

Interest Income

101

577

Income From Investment;

898

2,624

Investment Profit Recognized Under Equity Method

898

2,624

Income Gain

.

.

Gains on Sale of Fixed Assets

.

99

Foreign Exchange Gain

5,131

.

Financial assets evaluation interests

1,970

1,415

Financial liabilities evaluation interests

509

.

Miscellaneous Income

28,196

31,440

Non-operating expenses and losses

3,460

13,875

Interest Cost

3,460

3,232

Investment Losses

.

.

investment loss
recognized under equity method

.

.

Other investment loss

.

.

Loss On Exchange

.

10,118

Financial assets evaluation loss

.

.

Financial Liabilities evaluation loss

.

509

Miscellaneous Expenses

.

16

Income (loss)from continuing operations before income tax

139,431

197,902

Income tax expense (benefit)

10,834

25,315

Income tax expense (benefit)

10,834

25,315

Income (lossrom continuing operations

128,597

172,587

Net income (loss)

128,597

(USD 4,359,438)

172,587

(USD 5,850,699)

Basic EPS (Unit: NTD)

1.64

2.20

Diluted EPS (Unit: NTD)

1.63

2.19

(As of 2012.04, 1 NTD = 0.0339 USD)

 

 

Bankers

 

Subject declined to disclose its bank details; from other source we can not obtain the relevant information, either.

 

 

Public Record

 

Mortgage

No chattel mortgage record of subject has been found within the recent 3 months.

 

Lawsuit

Up to date of reporting, no existing or latent litigation of the subject has been found.

 


Interview Details

 

Department

Sales department

 

 


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.51.89

UK Pound

1

Rs.83.18

Euro

1

Rs.68.06

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

 

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.